Setmelanotide Lowers Weight, Hunger in Bardet-Biedl Syndrome, Phase 3 Trial Shows

Setmelanotide Lowers Weight, Hunger in Bardet-Biedl Syndrome, Phase 3 Trial Shows

281799

Setmelanotide Lowers Weight, Hunger in Bardet-Biedl Syndrome, Phase 3 Trial Shows

One year of treatment with setmelanotide was safe and resulted in a significant drop in body weight and hunger in Bardet-Biedl syndrome (BBS) patients, ages 12 years older, with moderate to severe obesity, according to top-line data from a Phase 3 clinical trial. “We are pleased with the robust response observed in BBS patients, which supports our goal of delivering a precision medicine to this well-characterized patient population who suffer from insatiable hunger and severe,…

You must be logged in to read/download the full post.